Under one in 10 patients that would benefit from obesity jabs like Wegovy can access them, states the World Health Organization as it issues its inaugural advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging more widespread and fairer availability to these injectable treatments.
Per estimates, more than two billion could be obese by 2030 without intervention.
"Our new guidelines affirms that excess weight is a lifelong illness that can be managed with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are major obstacles to broad availability to the treatments that can help people shift substantial weight, explains the organization.
GLP-1 Therapy Supply Crisis
Even under the present most optimistic scenario, the manufacturing of such drugs might only reach around 100 million people – under 10% of the global need, as stated by the health organization.
The recommendation calls on nations and manufacturers to expand access, through strategies such as patent sharing.
A patent on semaglutide – the main component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs mimick a natural hormone to slow digestion, curb appetite and boost feelings of fullness so people reduce food intake.
Individuals usually see weight reduction after several weeks of commencing the weekly injections.
Research points to patients may regain a significant portion after a year of discontinuing the treatment, as their normal food cravings return.
To be carrying excess weight raises your risk for experiencing health problems, including diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity impacts people in every country and was associated with over three and a half million deaths worldwide in 2024, as per the health agency.
